SOURCE: Goldman Small Cap Research, Inc.
BALTIMORE, MD--(Marketwired - Nov 1, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that in a move that could add meaningful value to the overall company, Plandaí Biotechnology, Inc. (OTCQB: PLPL) recently announced that it has formed a new wholly-owned subsidiary, Cannabis Biosciences, Inc., to develop and test a new Phytofare™ botanical extract derived from cannabis. Given Plandaí's unique bioavailability and extraction capabilities, the Company can make some serious inroads as an emerging player in this nascent space, relatively quickly. Conversely, many companies that have entered the space in recent months have done so in a transparent attempt to take advantage of the huge growth opportunity in the medical marijuana arena, despite lacking a coherent and value-added strategy or business model.
According to management, the Plandaí team has been working with cannabis for the past 12 months to determine if the Company's patent-pending process could produce a phyto-cannabinoid extract that exhibits the same high bioavailability of other Phytofare™ products. Once the current scientific viability model is concluded, preliminary bioavailability testing should commence in early 2014 with clinical trials commencing later in the year to pursue various pharmaceutical and nutraceutical applications.
The new extract will undergo a similar extraction process to the other Phytofare™ products and is expected to demonstrate the same high levels of bioavailability and purity. During the extraction process the company could also remove the psychoactive compound Tetrahydrocannabinol (THC), rendering a botanical drug that offers many of the medicinal benefits of cannabis without the perceived negative side effects.
There have been numerous studies in recent years citing the healing and treatment benefits of cannabinoids including Diabetes, ALS, Crohn's Disease, Multiple Sclerosis, and others. The largest constituent of cannabis, THC, has demonstrated the ability to reduce tumors and slow the progression of Alzheimer's. The second largest constituent of cannabis, which represents up to 40% of the extract, is Cannabidiol (CBD) which does not have psychoactive properties and will likely be the primary focus of the Company's testing in the near term.
Now that Plandaí has entered the cannabis market, observers and investors must take notice of the development progress which will have a direct and likely major positive impact on the value of the Company's stock in 2014.
This press release contains excerpts of our most recently published article on Plandaí. Goldman Small Cap Research sponsored articles, reports, and updates on Plandaí as well as associated disclaimers and disclosures can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Plandaí Biotechnology, Inc. (OTCQB: PLPL): Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts, which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing the patented pending Phytofare™ extracts in-house allowing the Company to guarantee the continuity of supply as well as quality control throughout Targeted industries for the Company's products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.